Well look here. Those two guys from in the details…, Tom Jefferson and Peter Doshi, just popped up again. I didn’t know we’d hear from them again within the week! And they brought a new friend. I know that the topic of Clinical Study Reports [CSRs] isn’t the sexiest of blog topics, but important things […]
[recent releases not shown] Among other things, one major change from the psychiatry I began with and the modern era was that I didn’t know which company produced which drug – or for that matter, which ones were on or off patent. I thought of the TCAs [Tricyclic Antidepressants] and the MAOIs [Monamine Oxidase Inhibitors] […]
Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports BMJ Open by Peter Doshi and Tom Jefferson 26 February 2013 [full text on-line] Objective To explore the structure and content of a non-random sample of clinical study reports [CSRs] to guide clinicians and systematic reviewers. Search strategy We searched […]
ABSTRACT- This article provides an overview of the use of paroxetine in the treatment of mood and anxiety disorders in children and adolescents. Although not currenty approved for use in patients younger than 18 years of age, the efficacy and safety of paroxetine have been studied in several pediatric mood and anxiety disorders. The epidemiology, […]
Note: POM = Primary Outcome Measures Is Mandatory Prospective Trial Registration Working to Prevent Publication of Unregistered Trials and Selective Outcome Reporting? An Observational Study of Five Psychiatry Journals That Mandate Prospective Clinical Trial Registration PLoS | ONE by Amelia Scott, Julia J. Rucklidge, and Roger T. Mulder August 19, 2015 Objective: To address the […]
As I’ve mentioned before, back in the early days of SSRIs, I was lucky to have a good friend whose wife, a sophisticated Social Worker, had taken Paxil shortly after it came on the market. When she stopped, she got ill and was perceptive enough to recognize that it wasn’t anything like her "depression coming […]
This time last year, I was feeling steamed that the pharmaceutical companies had been granted the right to treat the data from Clinical Trials as proprietary, private property, in the first place. That Law needed to be overturned! So I couldn’t find the Law and I wrote people in the know for help. They agreed […]
As a piece of their support of the movement for Data Transparency in Randomized Clinical Trials [RCTs], the BMJ featured a particular article [Restoring invisible and abandoned trials: a call for people to publish the findings] with this cover graphic [minus my added post-it notes] on their June 22, 2013 print edition: Since then, I […]
STAR*D was an elaborate NIMH study aiming to define some sequencing method that would improve the response to antidepressants using the algorithm on the left [as seen from space]. The main outcomes were a database mined for several hundred publications, a self-rating depression scale [QIDS-SR], and a template for future studies called naturalistic at the […]
While it’s not fashionable these days to acknowledge that Sigmund Freud even existed other than as a caricature, a container for the things he got wrong, this is one of those places where I would evoke something he got right – neutrality. Actually, his daughter Anna wrote it down in the most frequently quoted form, […]